Outpost Bio Raises $3.5M to Make the Human Microbiome “Computable”

London- and Boston-based Outpost Bio has secured $3.5 million in pre-seed financing to build a platform that links experimental microbiology with machine learning models of the human microbiome.

The round was co-led by Merantix Capital and Seedcamp, with participation from OpenSeed VC, Defined, and several strategic family offices and angel investors. The pre-seed capital will be allocated toward platform buildout, dataset expansion, and establishing partnerships with pharmaceutical and consumer-sector R&D teams. 

See also: What are Foundation Models in Biology and Healthcare?

Outpost Bio is focused on the human microbiome, the complex ecosystem of bacteria, fungi, and other microorganisms that influence drug metabolism, nutrient processing, and host physiology—what the company calls biology’s “hidden majority.” 

Outpost states its objective is to make these microbial ecosystems “computable” by pairing automated wet-lab experimentation with machine learning in a closed-loop system. Beyond building predictive models of how interventions alter microbial communities, Outpost says it intends to contribute foundational datasets and models to the broader scientific community and is actively seeking collaborators with well-characterized pre- and post-intervention microbiome datasets. 

While interest in microbiome research has grown across pharmaceutical, nutrition, and consumer health sectors, predictive modelling remains limited by fragmented workflows and high-dimensional biological data. 

Human microbiology presents technical challenges because microbial communities are dynamic, context-dependent, and shaped by nonlinear interactions among species and host factors. Data is often sparse, heterogeneous, and difficult to benchmark against clear biological ground truth. 

Outpost Bio’s aim is to turn these fragmented, high-dimensional microbiome data into computational infrastructure that can support more predictive and personalized approaches to medicine.

With live microbiota-based products now FDA-approved, the field is facing stronger pressure to translate microbiome signals into reproducible, regulator-facing evidence. Additionally, pharmaceutical and consumer health companies often rely on indirect assays or limited datasets when assessing microbiological interactions. A predictive framework grounded in experimental feedback may provide more quantitative support for preclinical decision-making.

Outpost Bio’s core platform, described as “Lab-in-the-Loop,” integrates automated experimentation with machine learning in a continuous feedback cycle. Experimental outputs are fed directly into models that inform subsequent experimental design. This closed-loop system is meant to reduce iteration time and improve model relevance by aligning data generation with predictive objectives in real time.

See also: Companies Making Automated Drug Discovery a Reality

The closed-loop approach aligns with the wider push toward self-driving laboratory workflows that integrate robotics and AI in closed experimental cycles, a model increasingly discussed as a practical route to faster iteration in biotech.

Recent examples across biotech include: 

• Turbine, which recently raised $25 million in Series B financing, is extending its AI “digital cell” models into immunology through proprietary perturbation datasets and pharma collaborations, operating a lab-in-the-loop cycle where wet-lab outputs iteratively refine virtual assays before further validation. 
• At the infrastructure layer, Thermo Fisher’s collaboration with NVIDIA and TetraScience aims to embed DGX, NeMo, and BioNeMo systems directly into instrument workflows, positioning AI models closer to experimental control and data generation across biopharma labs. 
• In small-molecule discovery, Ginkgo Bioworks’ Datapoints unit, Inductive Bio, and Tangible Scientific have linked ADMET prediction models with automated assay services and API-driven compound logistics, creating a closed design–test–learn loop. 

Cover image credit Outpost Bio

Topic: Biotech Ventures